Loading…
Newer Formulations of Risperidone: Remarks About Risperidone ISM
[...]as we already reported, the Risperidone ISM® product is reconstituted to an injectable suspension whose polymeric component precipitates in situ after an intramuscular injection, resulting in the formation of an implant, by solvent diffusion to body fluids. Risperidone is entrapped within that...
Saved in:
Published in: | CNS drugs 2020-10, Vol.34 (10), p.1087-1088 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | [...]as we already reported, the Risperidone ISM® product is reconstituted to an injectable suspension whose polymeric component precipitates in situ after an intramuscular injection, resulting in the formation of an implant, by solvent diffusion to body fluids. Risperidone is entrapped within that implant polymeric matrix, which biodegrades slowly providing a sustained release of drug for up to 1 month [5]. [...]Risperidone ISM® is not an emulsion comprising two phases (internal and external) nor one that comprises microparticles or microspheres, as Clark and Taylor state in their article [1]. [6], what is stated is that the product results in the formation of implants, not in microparticles or microspheres as Clark and Taylor state. [...]Risperidone ISM® is not an emulsion, it does not present several phases, and it does not lead to in situ microparticles/microspheres after administration. |
---|---|
ISSN: | 1172-7047 1179-1934 |
DOI: | 10.1007/s40263-020-00762-0 |